PMCQ Logo
 
Français|Sitemap 
Special Features

Ask PAAB

Search within Ask Paab

We have enhanced the Ask PAAB section to make it more user-friendly due to the growing number of questions. You can now select a category of interest from the drop down menu above to view existing question and answers or you can also do a search for questions that have been submitted to Ask PAAB since the beginning.

Most Recent Questions and Answers
554

On an HCP gated website that provides branded drug information, is it mandatory that the very first page after the gate is cleared be the "safety information" for that drug? Assuming the "safety information" link is accessible from the main navigation menu, can the landing page after the gate be some other content? Thanks.

  • View Answer [+]
553

Can you use "New" in APS for a product that has been on the market but has had their indication revised/expanded?

  • View Answer [+]
552

In the indication for a product has been updated (ie. expanded), can you put a "New" sticker on the front page of the Product Monograph for distribution to HCPs?

  • View Answer [+]
551

We have a patient survey conducted by a patient association looking at reasons for stopping therapy. Can we use this information in an unbranded APS to highlight the most common reasons for stopping therapy?

  • View Answer [+]
550

Can a company have a corporate pre-launch journal ad that speaks to an unmet need/care gap for a disease state that they don't yet have a product?

  • View Answer [+]
549

A company is entering into a new disease state in which they don't already market a product in Canada.If they produce a corporate ad (pre NOC) indicating that they are now entering into the therapeutic area/disease state, can they mention the therapeutic area/disease state in the ad?

  • View Answer [+]
548

1. Can a modified intent-to-treat (mITT) analysis be used in promotional materials? mITT analysis excluded patients who discontinued due to adverse event, lost to follow-up, or subject withdrawal. 2. If yes, would also need to show the primary endpoint analysis, ITT, as shown in the PM? 3. Are there any specific requirements on how the primary ITT and mITT analyses need to be displayed?

  • View Answer [+]
547

What type of reference is needed to claim absence of a specific excipient in a product? Would the fact that the specific excipient is not mentioned in the product monograph be enough to support this type of claim, or would some sort of certification of absence be required? For example, gluten free certification?

  • View Answer [+]
546

If I buy keywords that are associated to a gated website does it have to be submitted to PAAB? The targeted audience is consumer and not HCP. Thank you.

545

Are manufacturers and members of Rx&D mandated to submit all APS directed to HCPs to PAAB, including those that do not fall under PAAB exemption. Or, is it voluntary with the understanding APS should abide by the PAAB code.

  • View Answer [+]
Deputy Commissioner  

Patrick Massad
Deputy Commissioner

To view the PAAB
Code of Advertising Acceptance
click here
Pharmaceutical Advertising
Advisory Board
Upcoming meeting

January 23, 2018

Leading a Team to Victory

Cocktails: 5:30 p.m.
Dinner: 6:30 p.m.
Conference: 7:00 p.m.

Click here to register